|
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of phytonadione injectable emulsion USP, 10 mg/mL single dose ampules. Glenmark’s phytonadione injectable emulsion USP, 10 mg/mL single dose ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 injectable emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.
According to IQVIA sales data for the 12-month period ending November 2024, the Vitamin K1 injectable emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million.
Commenting on the launch, Marc Kikuchi, president & business head, North America said, “We are excited to announce the launch of phytonadione injectable emulsion USP, 10 mg/mL single dose ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.”
Glenmark Pharmaceuticals Ltd is a research-led, global pharmaceutical company, having a presence across Branded, Generics, And OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
|